Key Considerations for Summit Therapeutics Investors

By Chris Stiles • Saturday, July 27 15:08 • Permanent Link

With gains of 10.1%, Summit Therapeutics was one of the winners on Wall Street today. Its shares are now trading at $11.55 and have logged a 1.0% daily outperformance of the S&P 500. Don't join the feeding frenzy before checking some basic facts about this stock:

Summit Therapeutics has moved 450.0% over the last year, and the S&P 500 logged a change of 19.0%
SMMT has an average analyst rating of buy and is 8.25% away from its mean target price of $10.67 per share
Its trailing earnings per share (EPS) is $0.38
Summit Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of 30.4 while the S&P 500 average is 28.21
Its forward earnings per share (EPS) is $-0.29 and its forward P/E ratio is -39.8
The company has a Price to Book (P/B) ratio of 183.33 in contrast to the S&P 500's average ratio of 4.71
Summit Therapeutics is part of the Health Care sector, which has an average P/E ratio of 27.61 and an average P/B of 3.69
The company has a free cash flow of $-527605504, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.